In the last years, members of the CHMG Editorial Base were involved in many scientific projects, which aim to improve the methodology of systematic reviews, implement evidence based medicine in oncology and help patients in evidence based decision making. Behind the publication of results of systematic reviews in the Cochrane Library the results of all CHMG projects were also published in journals and presented at major conferences:

Publications in peer reviewed journals:

1. Skoetz N, Trelle S, Rancea M, Haverkamp H, Diehl V, Engert A, Borchmann P. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis. The Lancet Oncology. 2013;14(10):943-952 
2. Schlaak M, Theurich S, Pickenhain J, Skoetz N, Kurschat P, von Bergwelt-Baildon M. Allogeneic stem cell transplantation for advanced primary cutaneous T-cell lymphoma: A systematic review. Crit Rev Oncol Hematol. 2012 Jul 17.
   
3. Draube A, Klein-González N, Mattheus S, Brillant C, Hellmich M, Engert A, von Bergwelt-Baildon M. Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PloS one 2011;6(4):e18801.
4. Hübel K, Weingart O, Naumann F, Bohlius J, Fresen MM, Engert A, Wheatley K. Allogeneic stem cell transplant in adult patients with acute myelogenous leukemia: a systematic analysis of international guidelines and recommendations. Leuk Lymphoma. 2011 Mar;52(3):444-57. PubMed PMID: 21323525.
5. Raanani P, Skoetz N.The role of systematic reviews and meta-analyses in themanagement of hemato-oncological disorders. Introduction. Acta Haematol.2011;125(1-2):5-7. Epub 2010 Dec 8. PubMed PMID: 21150182.
6. Herbst C, Engert A. Meta-analyses of early-stage hodgkin lymphoma. Acta Haematol. 2011;125(1-2):32-8. Epub 2010 Dec 8. Review. PubMed PMID: 21150185.
7. Herbst C, Rehan FA, Brillant C, Bohlius J, Skoetz N, Schulz H, Monsef I, Specht L, Engert A. Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin lymphoma: a systematic review. 2010 Mar;95(3):494-500. Epub 2009 Nov 30.
8. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke M, Weingart O, Kluge S, Piper M, Rades D, Steensma DP, Djulbegovic B, Fey MF, Ray-Coquard I, Machtay M, Moebus V, Thomas G, Untch M, Schumacher M, Egger M, Engert A. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet. 2009; 373: 1532-1542.
9. Rizzo JD, Somerfield MR, Hagerty KL, Seidenfeld J, Bohlius J, Bennett CL, Cella DF, Djulbegovic B, Goode MJ, Jakubowski AA, Rarick MU, Regan DH, Lichtin AE. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood. 2008 Jan 1;111(1):25-41. Epub 2007 Oct 22. Review. Erratum in: Blood. 2008 Apr 1;111(7):3909. PubMed PMID: 17954703.
10. Rizzo JD, Somerfield MR, Hagerty KL, Seidenfeld J, Bohlius J, Bennett CL, Cella DF, Djulbegovic B, Goode MJ, Jakubowski AA, Rarick MU, Regan DH, Lichtin AE; American Society of Clinical Oncology; American Society of Hematology. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol. 2008 Jan 1;26(1):132-49. Epub 2007 Oct 22. Erratum in: J Clin Oncol. 2008 Mar 1;26(7):1192. PubMed PMID: 17954713.
11. Quellmann S, Schwarzer G, Hübel K,Engert A, Bohlius J. Corticosteroids in the prevention of graft-versus-host disease after allogeneic myeloablative stem cell transplantation: a systematic review and meta-analysis. Leukemia 2008 May 1;  22 (9): 1801-1803.  
12. Greb A, Bohlius J, Trelle S, Schiefer D, De Souza CA, Gisselbrecht C, Intragumtornchai T et al. High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma - Results of a comprehensive meta-analysis. Cancer Treatment Reviews 2007; 33 (4): 338-346.
13. Schulz H, Bohlius J, Trelle S, Skoetz N, Reiser M, Kober T, Schwarzer G et al. Immunochemotherapy With Rituximab and Overall Survival in Patients With Indolent or Mantle Cell Lymphoma: A Systematic Review and Meta-analysis. J Natl Cancer Inst 2007; 99 (9): 706-714.
14. Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M, Kearney N et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006; 42 (15): 2433-2453.
15. Bohlius J, Weingart O, Trelle S, Engert A. Cancer-related anemia and recombinant human erythropoietin--an updated overview. Nat Clin Pract Oncol 2006; 3 (3): 152-164.
16. Bohlius J, Engert A. Antibiotics plus granulocyte colony-stimulating factor reduces febrile neutropenia in the first cycle of chemotherapy in people with small-cell lung cancer. Cancer Treat Rev. 2006 May;32(3):234-8. Epub 2006 Apr 5. PubMed PMID: 16603317.
17. Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, Trelle S et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006; 98 (10): 708-714.
18. Kober T, Engert A. Neue Horizonte im Rahmen einer Evidenz-basierten Hämato-Onkologie: Bilanz und Stellenwert wissenschaftlicher Tätigkeiten der Cochrane Haematologcial Malignancies Group (CHMG). Z Arztl Fortbild Qualitatssich 2006; 100 (3): 167-174.
19. Kober T, Trelle S, Engert A. Reporting of randomized controlled trials in Hodgkin lymphoma in biomedical journals. J Natl Cancer Inst 2006; 98 (9): 620-625.
20. Seidenfeld J, Piper M, Bohlius J, Weingart O, Trelle S, Engert A, Skoetz N, Schwarzer G, Wilson J, Brunskill S, Hyde C, Bonnell C, Ziegler KM, Aronson N. Comparative Effectiveness of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2006 May. PubMed PMID: 20704045.
21. Steurer M, Pall G, Richards S, Schwarzer G, Bohlius J, Greil R. Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: a systematic review and meta-analysis. Cancer Treat Rev 2006; 32 (5): 377-389.
22. Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennett C, Engert A. Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 2005; 97 (7): 489-498.
23. Bohlius J, Langensiepen S, Engert A, Schwarzer G, Bennett CL. Effectiveness of erythropoietin in the treatment of patients with malignancies: methods and preliminary results of a Cochrane review. Best Pract Res Clin Haematol 2005; 18 (3): 449-454.
24. Kruger WH, Bohlius J, Cornely OA, Einsele H, Hebart H, Massenkeil G, Schuttrumpf S et al. Antimicrobial prophylaxis in allogeneic bone marrow transplantation. Guidelines of the infectious diseases working party (AGIHO) of the german society of haematology and oncology. Ann Oncol 2005; 16 (8): 1381-1390.
25. Skoetz N, Weingart O, Engert A. A consumer network for haematological malignancies. Health Expect 2005; 8 (1): 86-90.
26. Weingart O, Skoetz N, Lang B, Richter B, Engert A. Patientenbeteiligung in der Cochrane Collaboration - Barrieren, Erfahrungen und Konzepte aus deutscher Sicht. Z Arztl Fortbild Qualitatssich 2005; 99 (6): 367-371.
27. Bohlius J, Reiser M, Schwarzer G, Engert A. Impact of granulocyte colony-stimulating factor (CSF) and granulocyte-macrophage CSF in patients with malignant lymphoma: a systematic review. Br J Haematol 2003; 122 (3): 413-423.

Online Publications (CHMG biannual report series in JNCI)

1. Rancea M, Will A, Borchmann P, Monsef I, Engert A, Skoetz N. Fifteenth Biannual Report of the Cochrane Haematological Malignancies Group—Focus on Non-Hodgkin's Lymphoma.
   J Natl Cancer Inst. 2013; 105:1159-1170.
2. Rancea M, Skoetz N, Monsef I, Hübel K, Engert A, Bauer K. Fourteenth Biannual Report of the Cochrane Haematological Malignancies Group—Focus on Autologous Stem Cell Transplantation in Hematological Malignancies.
   J Natl Cancer Inst. 2012; 104(14).
3. Bauer K, Rancea M, Schmidtke B, Kluge S, Monsef I, Hübel K, Engert A, Skoetz N. Thirteenth Biannual Report of the Cochrane Haematological Malignancies Group--Focus on Multiple Myeloma.
   J Natl Cancer Inst. 2011 Jul 20; 103(17):E1-E19.
4. Skoetz N, Kluge S, Monsef I, Bauer K, Siebert H, Kreuzer KA, Engert A. Twelfth Biannual Report of the Cochrane Haematological Malignancies Group--Focus on Tyrosine Kinase Inhibitors.
   J Natl Cancer Inst.2011 Feb 16;103(4):E1.
5. Bauer K, Herbst C, Brillant C, Monsef I, Kluge S, Skoetz N, Engert A. Eleventh biannual report of the Cochrane Haematological Malignancies Group: Focus on Hodgkin lymphoma. 
   J Natl Cancer Inst. 2010 Jun 16;102(12):E1.
6. Bauer K, Skoetz N, Brillant C, Herbst C, Monsef I, Kluge S, Engert A.Tenth Biannual Report of the Cochrane Haematological Malignancies Group-Focus on Acute Myeloid Leukemia.
   J Natl Cancer Inst, 21 October 2009; 101: E1.
7. Skoetz N, Weingart O, Monsef I, Bauer K, Brillant C, Herbst C, Kluge S, Engert A. Ninth Biannual Report of the Cochrane Haematological Malignancies Group-Focus on Hematopoietic Growth Factors.
   J Natl Cancer Inst. 2009b; 101: E1.
8. Herbst C, Monsef I, Skoetz N, Engert A. Eighth Biannual Report of the Cochrane Haematological Malignancies Group--Focus on Chronic Lymphatic Leukemia.
   J Natl Cancer Inst.2008; 0: djn212v1-E1
9. Weingart O, Rehan FA, Schulz H, Naumann F, Knauel I, Brillant C, Bohlius J, Engert A. Sixth Biannual Report of the Cochrane Haematological Malignancies Group Focus on Non-Hodgkin Lymphoma.
   J Natl Cancer Inst 2007;99(17)E1
10. Naumann F, Weingart O, Kruse E, Schulz H, Bohlius J, Hulsewede H, Engert A. Fifth biannual report of the Cochrane Haematologic Malignancies Group--Focus on multiple myeloma.
    J Natl Cancer Inst 2006; 98 (16): E2
11. Kober T, Hulsewede H, Bohlius J, Engert A. Fourth Biannual Report of the Cochrane Haematological Malignancies Group.
    J Natl Cancer Inst 2006; 98 (8): E1
12. Kober T, Skoetz N, Trelle S, Bohlius J, Engert A. Third biannual report of the Cochrane Haematological Malignancies Group.
    J Natl Cancer Inst 2005b; 97 (16): E2
13. Kober T, Bohlius J, Trelle S, Engert A. Second biannual report of the Cochrane Haematological Malignancies Group.
    J Natl Cancer Inst 2005a; 97 (7): E1
14. Trelle S, Higgins G, Kober T, Engert A. Biannual report of the Cochrane Haematological Malignancies Group.
    J Natl Cancer Inst 2004; 96 (15): E2